TG Therapeutics, Inc.
Key Metrics
- Previous Close
- $62.71
- 52-Week Range
- $26.76 – $68.03
- Market Cap
- $9.99B
- P/E (TTM)
- 98.69
- EPS (TTM)
- 0.67
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 16.19
- PEG Ratio
- 1.61
- Return on Equity
- 17.99%
- Return on Assets
- 9.21%
- Gross Margin
- 82.74%
- Operating Margin
- 21.48%
- Profit Margin
- 11.81%
- Current Ratio
- 4.50
- Debt/Equity
- 1.32
- Total Debt
- $754.37M
- Free Cash Flow
- $85.52M
- Revenue Growth
- 60.70%
- Earnings Growth
- -85.60%
- Enterprise Value
- $9.51B
Market Snapshot
About
TG Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases, including chronic lymphocytic leukemia (CLL) and multiple sclerosis. The company markets BRIUMVI for relapsing forms of multiple sclerosis and continues advancing its pipeline of targeted immunotherapies.